In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avacta Pursues Combination Therapy Approach Targeting Solid Tumors

Executive Summary

Avacta CEO Alastair Smith talks to In Vivo about the company’s precision chemistry, immunotherapy and diagnostic programs.

You may also be interested in...



Biotech Foundations: Networks And Lab Space Are As Crucial As Funding

BioInnovation Institute chief business officer Bobby Soni shares how the life sciences incubator sources entrepreneurs and science globally, and the range of tools it provides to translate this into commercially viable companies. 

Lithuania Caps Off Decade Of Growth With Stellar 2020

Lithuania’s life sciences sector has harnessed the country’s talent, infrastructure and government support to realize a decade of unprecedented growth. With the industry now maturing, can the Baltic state overcome challenges to become a significant European player?

Execs On The Move, September 2021

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Topics

Related Companies

UsernamePublicRestriction

Register

IV124719

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel